Heme Iron Polypeptide in Iron Deficiency Anemia of Pregnancy: Current Evidence

Pal, Bhaskar; Deshpande, Hemant; Sundari, Tripura; Biniwale, Parag; Shah, Kamlesh; Goel, Sugandh; Khurana, Amandeep; Qamra, Amit; Motlekar, Salman; Barkate, Hanmant

doi:10.4236/ojog.2017.74044

Cited by 4 publications

(4 citation statements)

References 22 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The maternally absorbed 58Fe tracer present in the neonates was significantly high compared to 57Fe tracer (2.7±1.3 versus 2.2±1.4; respectively). This suggests that the heme-iron has favorable transport through the placenta to the fetus (21).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Abdelazim

Abu-Faza

Al-Ajmi

et al. 2021

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

OBJECTIVES: This study designed to compare the efficacy, and tolerability of heme-iron OptiFer® to ferrous fumarate in the treatment of iron deficiency anemia during pregnancy. STUDY DESIGN: Two hundred and thirty-four (234) women with iron deficiency anemia during pregnancy were included in this study; 121 women in the heme-iron OptiFer® group, and 113 women in the ferrous fumarate group. Women in the heme-iron OptiFer® group received OptiFer® tablets twice daily for ≥3 months then once daily as a maintenance dose. Women in the ferrous fumarate group received 350 mg oral ferrous fumarate once daily for ≥3 months. The pre-treatment ferritin, hemoglobin, red blood cells-mean corpuscular volume, and red blood cells-mean corpuscular hemoglobin were compared by the post-treatment values in the two studies. RESULTS: The post-treatment hemoglobin and ferritin were significantly high in the heme-iron OptiFer® group (11.2±7.1 gm/dL and 112.8±54.8 ug/l, respectively) compared to the ferrous fumarate group (10.9 ±5.1 and 89.9±43.3, respectively; p=0.0002 and p=0.006; respectively). The post-treatment red blood cells-mean corpuscular volume and red blood cells-mean corpuscular hemoglobin were significantly high in the heme-iron OptiFer® group (92.0±4.1 fl and 31.9±6.2 pg, respectively) compared to the ferrous fumarate group (87.7±2.9 and 28.5±4.7, respectively; p=0.0001 and p=0.001, respectively). The rates of poor compliance and gastrointestinal intolerance were significantly high in the ferrous fumarate group compared to the heme-iron OptiFer® group (12.4% and 19.5%, respectively versus 3.3% and 2.5%, respectively), (p=0.01 and p=0.0001, respectively). CONCLUSION: Heme-iron OptiFer® is an effective therapeutic option for the treatment of iron deficiency anemia during pregnancy with low side effects. heme-iron OptiFer® can be used in women who have low compliance, and/or gastrointestinal intolerance to conventional iron salts.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Abdelazim et al reported GIT intolerance/gastric upset in 1.7% (2/117) with HIP during the treatment of IDA with pregnancy (13). Pal et al, reported 4% poor compliance rate (<50% compliance) in the heme-iron treated group compared to 12% in the non-heme iron treated group(21).…”

mentioning

confidence: 98%

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Abdelazim

Abu-Faza

Al-Ajmi

et al. 2021

Gynecol Obstet Reprod Med

View full text Add to dashboard Cite

show abstract

“…16 Compared to conventional oral irons, haeme iron polypeptide has seven times greater bioavailability and negligible side effects, and is postulated to be absorbed by dual mechanisms. 17,18 Gastrointestinal absorption of haeme iron is far less affected by dietary constituents such as polyphenolic tannins, phytates, and soy and dairy products (calcium). 15,16,19 This could have also supplement in the improvement of IDA.…”

Section: Discussionmentioning

confidence: 99%

Severe, Refractory Anaemia Associated with Helicobacter Pylori Infection Managed With L. Reuteri DSMZ17648 (Probiotic) and Haeme Iron Supplements: A Case Report

Hinduja¹

2023

EMJ Gastroenterol

View full text Add to dashboard Cite

Helicobacter pylori infection can be observed with increased frequency in patients with iron deficiency anaemia (IDA), especially in resistant cases. This case report describes a case of resistant IDA that responded to probiotic (Lactobacillus reuteri DSMZ17648) and oral haeme iron polypeptide supplementation, highlighting that oral probiotic supplement trial may be considered before antibiotic therapy for H. pylori treatment in a patient with IDA.

show abstract

“…Thus, heme-bound iron is recommended as the first choice of iron supplementation to treat IDA during pregnancy and to maintain maternal iron stores. [ 34 ]…”

Section: Discussionmentioning

confidence: 99%

Heme-bound iron in treatment of pregnancy-associated iron deficiency anemia

Abdelazim

Abu-Faza²,

Shikanova

et al. 2018

J Family Med Prim Care

View full text Add to dashboard Cite

Background:The iron requirements increase during the second and third trimesters of pregnancy. Maternal anemia is a leading cause of adverse perinatal outcome.Objectives:This study was designed to evaluate the efficacy of the heme-bound iron in treatment of pregnancy-associated iron deficiency anemia (IDA).Materials and Methods:In all, 122 women with IDA during pregnancy and hemoglobin ≤10 g/dL were studied. The studied women were treated with heme-bound iron tablets for ≥3 months. Pretreatment hemoglobin, ferritin, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) were compared with the posttreatment values to detect the efficacy of heme-bound iron (Optifer®) in treatment of IDA during pregnancy.Results:The mean pretreatment hemoglobin significantly increased from 8.4 ± 2.7 to 11.2 ± 2.1 g/dL and the mean pretreatment ferritin level significantly increased from 22.6 ± 5.6 to 112.8 ± 4.8 μg/L (P < 0.003 and 0.04; respectively) 3 months after heme-bound iron treatment. In addition, the mean pretreatment red blood cells’ MCV and MCH significantly increased from 74.2 ± 4.8 fL and 24.2 ± 7.8 pg, respectively, to 92.0 ± 4.1 fL and 32.6 ± 6.2 pg) (P = 0.04 and 0.007, respectively) 3 months after heme-bound iron treatment.Conclusion:Heme-bound iron (Optifer®) is an effective oral iron preparation to treat IDA during pregnancy and to replace the depleted iron store.

show abstract

Heme Iron Polypeptide in Iron Deficiency Anemia of Pregnancy: Current Evidence

Cited by 4 publications

References 22 publications

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Heme-Iron OptiFer® in the Treatment of Iron Deficiency Anemia During Pregnancy

Severe, Refractory Anaemia Associated with Helicobacter Pylori Infection Managed With L. Reuteri DSMZ17648 (Probiotic) and Haeme Iron Supplements: A Case Report

Heme-bound iron in treatment of pregnancy-associated iron deficiency anemia

Contact Info

Product

Resources

About